Marine. Welcome aboard. I recommend immersing yourself in the patents for 48 hours. You won't understand most of it for another week. I didn't. And then the jigsaw . Papers etc etc starts making sense. Doesn't mean it will go up. But I do recommend it. All on the website..
found this while reading about ufos kidnapping one of the kardasians... anyway, too tired to drill down for original info but worth a couple of minutes, unless the EU Clinical Trials Directive isn't relevant here?
SAR believe that our selected best in class candidate CCT225737 outstrips the previous generation of CHK1 Inhibitors that were withdrawn by Merck and Pfizer after poor trials results. This is due to our candidates far greater selectivity and oral pharmacokinetics. Also those that are currently being investigated by Lilly ( intravenous administration only ) and Genentech appear to be inferior to ours. What predatory pharma would want to be out of this in the coming weeks and months?.
am sure nowhere near as efficacious as sars but gave some interesting numbers re. price... i'm still holding and looking for a rise, obviously, but a little contrary doesn't really hurt, just adds to context... plus it's damned recent.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.